BidaskClub lowered shares of R1 RCM (NASDAQ:RCM) from a hold rating to a sell rating in a research report report published on Saturday morning, BidAskClub reports.

Other analysts also recently issued research reports about the company. SVB Leerink began coverage on R1 RCM in a research note on Monday, April 13th. They set a market perform rating and a $10.00 target price for the company. Royal Bank of Canada began coverage on R1 RCM in a research report on Monday, April 20th. They issued an outperform rating and a $12.00 price objective for the company. Zacks Investment Research downgraded shares of R1 RCM from a hold rating to a sell rating in a research note on Thursday, May 7th. Finally, ValuEngine upgraded shares of R1 RCM from a hold rating to a buy rating in a research note on Tuesday, March 17th. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average target price of $13.43.

NASDAQ:RCM opened at $10.59 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 14.63. The company’s 50 day moving average is $10.83 and its 200-day moving average is $11.32. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -529.24, a P/E/G ratio of 12.03 and a beta of 0.52. R1 RCM has a 12 month low of $7.12 and a 12 month high of $13.99.

R1 RCM (NASDAQ:RCM) last announced its earnings results on Tuesday, May 5th. The healthcare provider reported $0.05 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.03). R1 RCM had a return on equity of 174.42% and a net margin of 2.44%. The firm had revenue of $320.50 million during the quarter, compared to the consensus estimate of $318.76 million. During the same quarter last year, the business earned ($0.04) EPS. The business’s revenue was up 16.1% compared to the same quarter last year. Research analysts predict that R1 RCM will post 0.08 EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. increased its stake in R1 RCM by 43.3% in the fourth quarter. Victory Capital Management Inc. now owns 44,690 shares of the healthcare provider’s stock valued at $559,000 after acquiring an additional 13,503 shares during the period. Rhumbline Advisers boosted its holdings in R1 RCM by 1.7% during the fourth quarter. Rhumbline Advisers now owns 140,299 shares of the healthcare provider’s stock valued at $1,821,000 after purchasing an additional 2,412 shares in the last quarter. Swiss National Bank raised its holdings in shares of R1 RCM by 3.6% in the 4th quarter. Swiss National Bank now owns 171,700 shares of the healthcare provider’s stock worth $2,229,000 after buying an additional 5,900 shares in the last quarter. State Street Corp lifted its position in shares of R1 RCM by 2.8% during the 4th quarter. State Street Corp now owns 2,257,033 shares of the healthcare provider’s stock worth $29,296,000 after buying an additional 61,577 shares during the period. Finally, Sei Investments Co. bought a new stake in shares of R1 RCM in the 4th quarter worth about $545,000. Institutional investors own 74.28% of the company’s stock.

R1 RCM Company Profile

R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers.

Featured Article: Fundamental Analysis and Choosing Stocks

Analyst Recommendations for R1 RCM (NASDAQ:RCM)

Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.